Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study.

Steve VucicRobert D HendersonSusan MathersMerrilee NeedhamDavid SchultzMatthew C Kiernannull null

Published in: Annals of clinical and translational neurology (2021)

Dimethyl fumarate, in combination with riluzole, was safe and well-tolerated in ALS. There was no significant improvement in the primary endpoint. The trial provides class I evidence for safety and lack of efficacy of dimethyl fumarate in ALS.

Keyphrases

amyotrophic lateral sclerosis
study protocol
clinical trial
randomized controlled trial
phase iii